Eight-year study finds distinct molecular paths in healthy aging

For eight years, researchers at King's College London returned to the same 335 people, tracking blood RNA, gene activity and metabolites. Their finding: healthy people of the same age can follow distinct molecular paths of aging, with some changes moving in markedly different — sometimes opposite — directions.

That matters because molecular aging is not simply a birthday count. It involves the steady accumulation of cellular damage and chemical changes in DNA, proteins and lipids, processes that can gradually weaken tissues and raise the risk of cancer, cardiometabolic disease and neurodegenerative disorders. The study found that genetic factors and environmental influences continuously interacted across participants' lifespans.

The differences were visible in specific biological signals. Participants with CXCL9, a gene linked to cardiac aging, showed different courses of change. Levels of TP53, a tumor suppressor gene, declined in certain individuals as they grew older, potentially altering their cancer risk. The researchers also reported correlations between changing blood levels of PFAS — often called forever chemicals — and evolving molecular profiles.

The immune system did not age along one uniform track either. Molecular changes differed between innate immunity, the fast first line of defense people are born with, and adaptive immunity, the slower response that builds memory over time. Professor Kerrin Small of King's College London said the findings could help distinguish healthy aging from the earliest stages of disease.

Concretely, the immediate result is a more individualized map of aging, not a new treatment. The potential payoff is that people whose molecular patterns suggest higher disease risk could eventually receive earlier, more targeted care, while environmental health measures could be assessed through their effects at the molecular level.

The study followed one cohort and reports correlations for environmental exposures; its TP53 finding is described as potentially affecting cancer risk. Its authors present the work as a possible roadmap for precision medicine, with the practical applications still ahead.